4.5 Article

Myocarditis following COVID-19 vaccination-A case series

Journal

VACCINE
Volume 39, Issue 42, Pages 6195-6200

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.09.004

Keywords

Myocarditis; COVID-19; Vaccines

Ask authors/readers for more resources

The incidence rate of myocarditis in the week following the second dose of the Pfizer-BioNTech COVID-19 vaccine was 5.07/100,000 vaccinated individuals, with all cases exhibiting mild disease and no sequela. Further investigation is needed to determine the true incidence rates and causality.
There have been reports of myocarditis following COVID-19 vaccination. We surveyed all hospitalized military personnel in the Isareli Defense Forces during the period of the COVID-19 vaccination operation (12/28/2021-3/7/2021) for diagnosed myocarditis. We identified 7 cases of myocarditis with symptoms starting in the first week after the second dose of COVID-19 Pfizer-BioNTech vaccine. One case of myocarditis diagnosed 10 days after the second dose of the vaccine was not included. These 8 cases comprise of all events of myocarditis diagnosed in military personnel during this time period. All patients were young and generally healthy. All had mild disease with no sequalae. The incidence of myocarditis in the week following a second dose of the vaccine was 5.07/100,000 people vaccinated. Due to the nature of this report no causality could be established. Clinicians should be aware of the possibility of myocarditis following Pfizer-BioNTech vaccination. True incidence rates should be further investigated. (c) 2021 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available